M1 Kliniken AG Reports Strong Financial Performance with 11% EBIT Growth and Strategic Focus on Medical Aesthetics

M1 Kliniken AG successfully closed the last nine months of 2025, continuing its profitable growth trajectory with consistent implementation of efficiency measures and targeted expansion of medical capacities contributing significantly to improved profits. Group revenue increased by 6.7% to EUR 274.3 million compared to EUR 257.2 million in the same period of 2024, while EBITDA grew by 9% to EUR 28.2 million from EUR 25.9 million previously. The company achieved an 11% increase in EBIT to EUR 24.5 million, up from EUR 22.1 million in the prior year period, with the EBIT margin improving to 8.9% from 8.6%. Earnings before tax rose by 10% to EUR 24.4 million, and earnings per share reached EUR 0.86 compared to EUR 0.77 in the first nine months of 2024.

The Beauty segment demonstrated particularly strong performance, serving as the key growth driver for the Group with revenue increasing by 9.5% to EUR 77.8 million from EUR 71.0 million in the comparable period. EBIT in the Beauty segment surged by 29.7% to EUR 21.1 million, up from EUR 16.3 million, while the EBIT margin expanded significantly to 27.1% from 22.9%. The positive development seen in the first half of the year continued convincingly in the third quarter of 2025, with the segment benefiting from efficiency gains through optimized processes and higher utilization of medical capacities. A targeted pricing strategy aimed at attracting new customer groups supported market share expansion without compromising margin quality, consistent with the company's positioning as the leading provider of high-quality aesthetic medicine at competitive prices.

The Trading segment recorded solid revenue growth of 6% to EUR 196.5 million from EUR 186.2 million in the prior year period, though EBIT decreased by 41.4% to EUR 3.4 million compared to EUR 5.8 million previously. M1 Kliniken AG announced that its 85% subsidiary, HAEMATO AG, has signed an agreement to sell its wholly owned subsidiary HAEMATO Pharm GmbH to the PHOENIX group, one of Europe's leading healthcare providers based in Mannheim, with the transaction subject to usual antitrust approvals. This strategic move aligns with M1 Kliniken AG's focused approach to positioning itself as the world's leading vertically integrated pure-play provider of medical aesthetics.

Looking forward, M1 Kliniken AG will continue its profitable growth trajectory by expanding its network of national and international clinics. The company has set ambitious targets, expecting to increase revenue to between EUR 200 million and EUR 300 million by 2029 while maintaining a sustainable EBIT margin of at least 20%. The Group remains committed to establishing M1 Med Beauty as the world's leading brand for aesthetic medicine through consistent strategic execution and market expansion. The company's performance reflects successful implementation of operational efficiencies and strategic focus on high-growth segments within the medical aesthetics market.